Over time, the introduction of receptor-targeted or phenotype-specific radioligands (e.g., for somatostatin receptors in neuroendocrine tumors, or prostatic specific membrane antigene—PSMA in prostate cancer) further extended PET’s diagnostic and prognostic utility [3]. This evidence concerns the gene FOLH1 and Familial prostate cancer.